Patents by Inventor Benjamin Edward Kang

Benjamin Edward Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION
    Publication number: 20220265609
    Abstract: Transforming growth factor ? (TGF?) transcriptional responses are involved in the pathogenesis of aortic aneurism syndromes. Compositions that inhibit histone acetyltransferase activity normalize gene expression in the aorta, preserved aortic wall architecture and abrogated aneurism progression. Methods include the use of these compositions to epigenetically regulate abnormal expression and/or activity of TGF? genes.
    Type: Application
    Filed: February 4, 2022
    Publication date: August 25, 2022
    Inventors: Harry C. Dietz, Benjamin Edward Kang
  • Targeted epigenetic therapy for inherited aortic aneurysm condition
    Patent number: 11273148
    Abstract: Transforming growth factor ? (TGF?) transcriptional responses are involved in the pathogenesis of aortic aneurism syndromes. Compositions that inhibit histone acetyltransferase activity normalize gene expression in the aorta, preserved aortic wall architecture and abrogated aneurism progression. Methods include the use of these compositions to epigenetically regulate abnormal expression and/or activity of TGF? genes.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: March 15, 2022
    Assignee: The Johns Hopkins University
    Inventors: Harry C. Dietz, Benjamin Edward Kang
  • TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION
    Publication number: 20200253932
    Abstract: Transforming growth factor ? (TGF?) transcriptional responses are involved in the pathogenesis of aortic aneurism syndromes. Compositions that inhibit histone acetyltransferase activity normalize gene expression in the aorta, preserved aortic wall architecture and abrogated aneurism progression. Methods include the use of these compositions to epigenetically regulate abnormal expression and/or activity of TGF? genes.
    Type: Application
    Filed: August 31, 2018
    Publication date: August 13, 2020
    Inventors: Harry C. Dietz, Benjamin Edward Kang